Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the potential of BNT327, a bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, in development by BioNTech and the results presented at the ESMO Congress in patients with NSCLC

Ticker(s): BNTX

Who's the expert?

Institution: UH Seidman Cancer Center

· Manages 60 patients with NSCLC
· Prescribed Lumakras to 4 patients so far

Interview Goal

Discussing the potential of BNT327/PM8002, an investigational bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization, in development by BioNTech and the results presented at the ESMO Congress in an oral presentation titled, “A Phase II Safety and Efficacy Study of PM8002/BNT327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)”.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.